Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Captopril and enalapril are approved for infants and children; however, lisinopril is only approved for 7 years of age. This study evaluated safety and efficacy of converting from captopril to lisinopril in patients utilizing a pre-defined conversion of 3 mg captopril to 1 mg lisinopril.
Objective: To provide clinical support that conversion from captopril to lisinopril at a daily oral dosage ratio of 5:1 maintains comparable therapeutic efficacy, and to estimate retrospectively cost savings because of conversion from captopril to lisinopril therapy at the study site and with the associated overall drug conversion program instituted by Kaiser Permanente.
A synthesis was not conducted by the authors since lisinopril therapy was a weakly dominant strategy. The conversion from captopril (in
Continuing the use of captopril or switching to lisinopril therapy at an initial daily conversion ratio of captopril 5 mg to lisinopril 1 mg
A synthesis was not conducted by the authors since lisinopril therapy was a weakly dominant strategy. The conversion from captopril (in
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Angiotensin converting enzyme (ACE) inhibitors, such as lisinopril, enalapril, ramipril, benazepril, and captopril, block the conversion of
Captopril and lisinopril are the only ACE inhibitors that do not require hepatic conversion to active metabolites and may be preferred in
Comments